Drugs / Universal Donor Expanded TGF-beta-imprinted NK Cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07144384 | Oct 2025 → Apr 2026 overdue | nodular basal cell carcinoma, skin squamous cell carcinoma | Ohio State University Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06203912 | Mar 2024 → May 2026 | plasma cell myeloma | Elvira Umyarova | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06026657 | Apr 2024 → Dec 2026 expected | Her2-receptor negative breast cancer | Margaret Gatti-Mays | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05588453 | Mar 2023 → Apr 2027 expected | cutaneous melanoma, metastatic malignant neoplasm in the brain, metastatic melanoma | Kari Kendra | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal Donor Expanded TGF-beta-imprinted NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144384 ↗ |
| Known as | UD TGFbetai NK cells | “Patients receive UD TGFbetai NK cells intravenously (IV) over 30 minutes on day 1 and temozolomide orally (PO) daily on days 1-5.” NCT05588453 ↗ |
| Action | Deplete | “NK cells can recognize missing or incorrect proteins on tumor cells and then eliminate these tumor cells” NCT06026657 ↗ |
| Modality | Cell therapy | “universal donor UD TGFbetai natural killer (NK) cells” NCT05588453 ↗ |
| Route | Intravenous | “UD TGFbetai NK cells intravenously (IV) over 30 minutes on day 1” NCT05588453 ↗ |